Renal cell carcinoma
Conditions
Interventions
Gold Standard:Clinical outcomes based on RECIST criteria
Index test:Multigene Panels (For details, please refer to the Chinese patent application [202210555507.8, Application of gene combination in preparation of products for graded detection of human tumor
Sponsors
Peking University First Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: ? Patients with renal cell carcinoma ? With indications for immunotherapy (initial immunotherapy) ? With imaging assessable lesions ? Paraffin specimen sections for DNA extraction could be obtained ? Patients agree to participate in the study and sign an informed consent form ? Patients should be adults and not belong to a vulnerable group
Exclusion criteria
Exclusion criteria: ? Patients with contraindications to immunotherapy ? Patient has a life expectancy of less than six months ? Patients refuse to participate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sensitivity;Specificity;Positive predictive value;Negative predictive value; | — |
Secondary
| Measure | Time frame |
|---|---|
| TMB;MSI;HRD;OS;CSS;PFS; | — |
Countries
China
Contacts
Public ContactGengyan Xiong
Peking University First Hospital
Outcome results
None listed